Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically-Based Pharmacokinetic Simulations

Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families

(2011) T. W. Wong et al.   CLINICAL CANCER RESEARCH

In Vitro Characterization of the Metabolic Pathways and Cytochrome P450 Inhibition and Induction Potential of BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor

(2011) H. Hong et al.   DRUG METABOLISM AND DISPOSITION

Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model

(2011) Helen E. Cubitt et al.   XENOBIOTICA

Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans

(2010) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Preclinical Pharmacokinetics and In Vitro Metabolism of BMS-690514, a Potent Inhibitor of EGFR and VEGFR2

(2010) Punit Marathe et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer

(2009) Catherine Gérard et al.   Molecular Oncology

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

(2009) N. A. Pennell et al.   ONCOLOGIST